NAD Recommends Maximum Human Performance Discontinue Claims at Issue for ‘MYO-X Myostatin Inhibitor’
New York, NY – Oct. 16, 2013 – The National Advertising Division has recommended that Maximum Human Performance, LLC, which markets the dietary supplement MYO-X Myostatin Inhibitor, discontinue the advertising claims and testimonials at issue in NAD’s review.
NAD is an investigative unit of the advertising industry’s system of self-regulation. It is administered by the Council of Better Business Bureaus.
As part of NAD’s routine monitoring efforts, and in conjunction with an initiative with the Council for Responsible Nutrition designed to expand NAD’s review of advertising claims for dietary supplements, NAD requested substantiation for claims that appeared in print advertising, on product packaging and on the advertiser’s website, including:
Express Claims:
- “Research has shown that a reduction in serum myostatin levels is likely to result in clinically significant muscle gains. In my work with elite athletics I have seen firsthand the muscle enhancement impact of MYO-X when used in conjunction with intense weight training. These athletes have made vast improvements in muscle size, strength, performance and improved recovery.”
- “Backed by more than a decade of evolutionary bench work and published scientific research showing it can truly reduce human myostatin levels!”
- “The most exciting muscle building breakthrough the world has ever seen!”
- “Clinically shown to reduce myostatin in 100% of human test subjects by an average of 46% in only 12 – 18 hours.”
- “Clinically tested and shown to suppress myostatin in 100% of human test study subjects and reduce blood levels of myostatin by an average of 46% in only 12 – 18 hours!”
- “The World’s Only Clinically Tested Natural Myostatin Inhibitor.”
Testimonials:
- “A new breakthrough in muscle building and body transformation science.”
- “A monumental advancement in muscle enhancement and performance nutrition. MHP is once again leading the industry into a new frontier.”
- “I’ve never experienced anything like MYO-X. This stuff has extremely powerful muscle building and recovery efforts.”
- “If you’re looking to get bigger and stronger, you need MYO-X. It truly activates muscle growth and speeds recovery faster than anything I’ve ever taken.”
By way of background, the advertiser explained that MYO-X is a beverage mix dietary supplement formulated to reduce the levels of a biological molecule called myostatin, which inhibits muscle differentiation and growth.
As support for its advertising claims, NAD noted, the company relied on scientific literature and studies that did not address whether ingesting the product did in fact reduce myostatin levels in a manner that resulted in “clinically significant” muscle gains or muscle performance benefits.
NAD noted that while the evidence in the record “shows promising results in support of the theory that ingestion of MYO-X will reduce human myostatin levels and result in a muscle enhancement impact, the evidence fails to establish the causal link necessary to support the claims at issue.”
Following its review, NAD recommended that the advertiser discontinue express claims and testimonials at issue.
The company, in its advertiser’s statement, said it “appreciated the opportunity to participate in the self-regulatory process, however, the company and the leading researcher on the benefits of Myostatin suppression disagrees with the NAD’s assessment of the underlying science and initial studies behind MYO T-12.”
However, the company said, it “will modify its claims to conform to NAD’s decision and will develop claims based on the outcome of future clinical studies.”
Subscribe to the Ad Law Insights or Privacy Initiatives newsletters for an exclusive monthly analysis and insider perspectives on the latest trends and case decisions in advertising law and data privacy.
Latest Decisions
National Advertising Division Recommends Oral Essentials Discontinue "Certified Non-Toxic" Claim for its Lumineux Mouthwash
New York, NY – December 30, 2024 – In a Fast-Track SWIFT challenge brought by GuruNanda, the National Advertising Division recommended that Oral Essentials discontinue its claim that Lumineux mouthwash products are “Certified Non-Toxic.”
NARB Recommends T-Mobile Discontinue or Modify Commercial to Better Disclose Conditions of Free iPhone Offer, 20% Savings Claim
New York, NY – December 30, 2024 – A panel of the National Advertising Review Board (NARB) recommended that T-Mobile discontinue or modify its commercial to better disclose the material conditions of its free iPhone 16 Pro offer and its 20% rate plan savings claim compared to AT&T and Verizon.
Direct Selling Self-Regulatory Council Recommends Valentus Discontinue Earnings and Product Performance Claims
McLean, VA – December 23, 2024 – The Direct Selling Self-Regulatory Council (DSSRC) recommended Valentus, a direct selling company that sells nutritional and lifestyle products, discontinue earnings and health-related product performance claims made on social media and on the Valentus website.
Direct Selling Self-Regulatory Council Refers Olive Tree Earnings Claims to the FTC and California AG for Possible Enforcement Action
McLean, VA – December 20, 2024 – The Direct Selling Self-Regulatory Council (DSSRC) referred Olive Tree to the Federal Trade Commission (FTC) and California Attorney General's Office for possible enforcement action after Olive Tree failed to respond to a DSSRC inquiry into earnings claims.